[HTML][HTML] The role of roxadustat in chronic kidney disease patients complicated with anemia
J Liu, F Yang, Y Waheed, S Li, K Liu… - The Korean Journal of …, 2023 - ncbi.nlm.nih.gov
The incidence of chronic kidney disease (CKD) is increasing worldwide and the current
prevalence rate is 13.4%. There are> 120 million CKD patients in China and this number is …
prevalence rate is 13.4%. There are> 120 million CKD patients in China and this number is …
[PDF][PDF] 血清25 (OH) D, NGAL, Hepcidin 与罗沙司他胶囊治疗维持性血液透析患者肾性贫血临床疗效的关系研究
刘阳， 李雷， 汤伟， 孙东， 程坤 - Progress in Modern …, 2024 - biomed.cnjournals.com
摘要目的: 探讨血清25 羟维生素D [25 (OH) D], 中性粒细胞明胶酶相关脂质运载蛋白(NGAL),
铁调素(Hepcidin) 与罗沙司他胶囊治疗维持性血液透析(MHD) 患者肾性贫血临床疗效的关系 …
铁调素(Hepcidin) 与罗沙司他胶囊治疗维持性血液透析(MHD) 患者肾性贫血临床疗效的关系 …
Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised, multicentre, open-label …
P Li, X Sun, D Chen, H Lin, L Zhang, Y Wu, S Pan… - BMJ open, 2023 - bmjopen.bmj.com
Introduction Roxadustat is a first-in-class oral therapy that treats chronic kidney disease
(CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects …
(CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects …
罗沙司他治疗腹膜透析贫血疗效及对腹膜转运能力变化的影响.
任荣， 陈凯旋， 张静， 曹冰， 姜鸿 - Practical Pharmacy & …, 2024 - search.ebscohost.com
目的观察罗沙司他治疗腹膜透析贫血的疗效及其对腹膜溶质转运能力变化的影响.
方法纳入新疆医科大学第五附属医院和新疆自治区人民医院2022 年1 月至2023 年1 …
方法纳入新疆医科大学第五附属医院和新疆自治区人民医院2022 年1 月至2023 年1 …
[PDF][PDF] 糖尿病肾病维持性血液透析患者低血糖发生情况及其影响因素的Logistic 回归分析
贾文姬， 李路玲， 秦晓新， 翟红霞… - Progress in Modern …, 2023 - biomed.cnjournals.com
摘要目的: 探讨糖尿病肾病(DN) 维持性血液透析患者低血糖发生情况, 并分析其影响因素. 方法:
选择2018 年7 月~ 2021 年2 月期间收治的100 例DN 维持性血液透析患者 …
选择2018 年7 月~ 2021 年2 月期间收治的100 例DN 维持性血液透析患者 …
[HTML][HTML] Protocol: Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised …
P Li, X Sun, D Chen, H Lin, L Zhang, Y Wu, S Pan… - BMJ Open, 2023 - ncbi.nlm.nih.gov
Introduction Roxadustat is a first-in-class oral therapy that treats chronic kidney disease
(CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects …
(CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects …
Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
YWX Yub - 2024 - karger.com
Background: Anemia is one of the common complications of chronic kidney disease (CKD),
and its prevalence has been arising globally. The key cause of anemia in CKD patients is …
and its prevalence has been arising globally. The key cause of anemia in CKD patients is …
Roxadustat―new therapeutic option for treatment of anemia in patients with chronic kidney disease
A Chamienia, A Dębska-Ślizień - Renal Disease and …, 2022 - journals.viamedica.pl
Chronic kidney disease (CKD) is an increasingly common public health issue. It is estimated
that it affects 8–16% of the global population. Anemia is a very common complication of …
that it affects 8–16% of the global population. Anemia is a very common complication of …
Roxadustat for Patients with Posttransplant Anemia: A Narrative
XTFLQL JianhuaMao - 2023 - karger.com
Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral
agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating …
agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating …
Хроническая болезнь почек: диагностика, ведение и терапия ассоциированной анемии
АЛ Верткин, ЕА Прохорович, ГЮ Кнорринг - Терапия, 2022 - elibrary.ru
В многочисленных международных исследованиях установлено, что хроническая
болезнь почек (ХБП) столь же широко распространена, как и наиболее социально …
болезнь почек (ХБП) столь же широко распространена, как и наиболее социально …